Listen to article
6:36Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 17 October 2026
Read article
Published on 17 October 2026
Read article
Published on 17 October 2026
Read article
Published on 17 October 2026
Read article
Published on 16 October 2026
Read article
Let’s be honest, when a company like GSK drops half a billion dollars on something, you tend to sit up and take notice. Their recent deal with a Chinese firm, Jiangsu Hengrui, wasn’t just another line item in an annual report. To me, it felt more like a flare being shot into the night sky, signalling a profound shift in the pharmaceutical world. For years, the giants of the industry operated with a certain swagger, a belief that all the best ideas were born in their own gleaming, expensive laboratories. That era, it seems, is drawing to a rather abrupt close.
The simple truth is that Big Pharma is in a bit of a pickle. Their blockbuster drugs, the ones that have been printing money for decades, are falling off the patent cliff one by one. Their own research pipelines are notoriously slow and eye-wateringly expensive. It’s like a Michelin-starred chef suddenly realising they’ve run out of their signature ingredients and the pantry is looking bare. What do you do? You go shopping. And right now, the most interesting new market appears to be in China.
For a long time, the words ‘Made in China’ brought to mind electronics and textiles, not cutting-edge cancer treatments. But while we were all distracted, something remarkable was happening. Chinese biotech companies have been quietly building world-class research facilities. They’ve been developing novel drug candidates with a speed and cost-efficiency that makes their Western counterparts look a bit sluggish.
It’s a perfect storm, really. You have the desperate buyers, the global pharma giants, who need new products to keep their shareholders happy. Then you have the eager sellers, the Chinese innovators, who have a portfolio of promising drugs that need funding and global distribution to reach their potential. The regulatory hurdles are also getting lower, with Chinese clinical trials increasingly meeting tough international standards. It’s a marriage of convenience, perhaps, but one that could prove incredibly lucrative for both sides.
Of course, not all companies are created equal. A few names keep cropping up as being particularly well-placed to ride this wave. You have firms like Hutchison China MediTech, which has already proven it can build partnerships to develop its cancer treatments. Then there’s Zai Lab, which has a clever model of finding promising drugs and developing them for Asian markets, and I-Mab, with its pipeline focused on cancer and autoimmune diseases.
What these companies have in common is a blend of solid science, experienced leadership, and a portfolio of potential solutions to some of medicine’s biggest problems. For an investor, the announcement of a partnership with a global giant can be transformative. It’s not just about the money, though the upfront payments and potential royalties are certainly attractive. It’s a validation. It’s the market saying, yes, your science is the real deal. For those looking to tap into this trend without betting the farm on a single company, a diversified approach through something like the China's Biopharma Innovators basket might make sense.
Now, before we all get carried away, a word of caution. Investing in biotechnology is not for the faint of heart. It is a high-stakes game of chance. For every drug that makes it through clinical trials and gets approved, countless others fail, taking billions in investment with them. A promising candidate can fall at the final hurdle, and a company’s stock price can plummet overnight. Add to that the usual risks of investing in China, from regulatory shifts to currency fluctuations, and you have a recipe for volatility. This is not a ‘get rich quick’ scheme. It’s a calculated risk on a powerful, emerging trend. The GSK deal wasn’t the start of the race, it was merely the firing of the starting pistol. The race itself will be a marathon, not a sprint.
View the full Basket:China's Biopharma Innovators: The Next Global Partnership Wave
View the full Basket:China's Biopharma Innovators: The Next Global Partnership Wave
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 17 October 2026
Read article
Published on 17 October 2026
Read article
Published on 17 October 2026
Read article
Published on 17 October 2026
Read article
Published on 16 October 2026
Read article
